<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id>
<journal-title>Frontiers in Aging Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Aging Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1663-4365</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnagi.2021.754956</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Curcumin Reduced H<sub>2</sub>O<sub>2</sub>- and G2385R-LRRK2-Induced Neurodegeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhang</surname> <given-names>Jinru</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Kai</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Xiaobo</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Smith</surname> <given-names>Amber M.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ning</surname> <given-names>Bo</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Zhaohui</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1379294/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Chunfeng</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/336502/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ross</surname> <given-names>Christopher A.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/153457/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Smith</surname> <given-names>Wanli W.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/393825/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Human Anatomy and Cytoneurobiology, School of Biology and Basic Medical Sciences, Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Institute of Neuroscience, Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Xiongwei Zhu, Case Western Reserve University, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Yinxia Chao, National Neuroscience Institute (NNI), Singapore; Vinita Ganesh Chittoor, Stanford University, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Wanli W. Smith <email>wsmith60&#x00040;jhmi.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>13</volume>
<elocation-id>754956</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2021 Zhang, Li, Wang, Smith, Ning, Liu, Liu, Ross and Smith.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Zhang, Li, Wang, Smith, Ning, Liu, Liu, Ross and Smith</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license></permissions>
<abstract><p>Mutations in <italic>leucine-rich repeat kinase 2 gene</italic> (<italic>LRRK2</italic>) are the most frequent genetic factors contributing to Parkinson&#x00027;s disease (PD). G2385R-<italic>LRRK2</italic> increases the risk for PD susceptibility in the Chinese population. However, the pathological role of G2385R-<italic>LRRK2</italic> is not clear. In this study, we investigate the roles of G2385R-LRRK2 in neurodegeneration underlying PD pathogenesis using cell biology and pharmacology approaches. We demonstrated that expression of G2385R-LRRK2-induced neurotoxicity in human neuroblastoma SH-SY5Y and mouse primary neurons. G2385R-LRRK2 increased mitochondrial ROS, activates caspase-3/7, and increased PARP cleavage, resulting in neurotoxicity. Treatment with curcumin (an antioxidant) significantly protected against G2385R-LRRK2-induced neurodegeneration by reducing mitochondrial ROS, caspase-3/7 activation, and PARP cleavage. We also found that the cellular environmental stressor, H<sub>2</sub>O<sub>2</sub> significantly promotes both WT-LRRK2- and G2385R-LRRK2-induced neurotoxicity by increasing mitochondrial ROS, caspase-3/7 activation, and PARP cleavage, while curcumin attenuated this combined neurotoxicity. These findings not only provide a novel understanding of G2385R roles in neurodegeneration and environment interaction but also provide a pharmacological approach for intervention for G2385R-LRRK2-linked PD.</p></abstract>
<kwd-group>
<kwd>LRRK2-G2385R</kwd>
<kwd>curcumin</kwd>
<kwd>oxidative stress</kwd>
<kwd>ROS</kwd>
<kwd>H<sub>2</sub>O<sub>2</sub>&#x02013;hydrogen peroxide</kwd>
<kwd>Parkinson&#x00027;s disease</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></contract-sponsor>
<counts>
<fig-count count="6"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="35"/>
<page-count count="8"/>
<word-count count="4918"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Parkinson&#x00027;s disease (PD) is the second most common neurodegenerative disease with movement disorders. The clinical symptoms include bradykinesia, myotonia, and rest tremor, and the pathological features include loss of dopaminergic neurons in the substantia nigra and the deposition of protein aggregates, lewy bodies (Kalia and Lang, <xref ref-type="bibr" rid="B9">2015</xref>). Mutations in <italic>leucine-rich repeat kinase 2 gene</italic> (<italic>LRRK2</italic>) are recognized as the most frequent genetic factors contributing to familial and sporadic PD. The proportion of <italic>LRRK2</italic> gene mutations in autosomal-dominant PD patients is about 5&#x02013;15%, and in sporadic PD patients it is 1&#x02013;3% (Healy et al., <xref ref-type="bibr" rid="B6">2008</xref>). According to the Human Gene Mutation Database, more than 100 <italic>LRRK2</italic> variants have been reported to be associated with PD (<ext-link ext-link-type="uri" xlink:href="http://www.hgmd.cf.ac.uk/ac/index.php">http://www.hgmd.cf.ac.uk/ac/index.php</ext-link>). Among those variants, G2019S is the most frequently reported mutation in the Caucasian population, but it is rare in the Asian population (Clark et al., <xref ref-type="bibr" rid="B4">2006</xref>; Healy et al., <xref ref-type="bibr" rid="B6">2008</xref>; Lee et al., <xref ref-type="bibr" rid="B10">2017</xref>). Genetic studies indicate that about 5.5% of sporadic PD patients carried the G2385R (Xie et al., <xref ref-type="bibr" rid="B30">2014</xref>) variant in the Asian population. G2385R increases the risk for PD susceptibility by two to three folds (Healy et al., <xref ref-type="bibr" rid="B6">2008</xref>; Zhang et al., <xref ref-type="bibr" rid="B34">2018</xref>). However, the neuropathological roles of G2385R-LRRK2 are not fully understood.</p>
<p>LRRK2 is a multiple-domain protein containing a kinase domain, a GTPase domain, and a WD40 domain (Liu et al., <xref ref-type="bibr" rid="B13">2016</xref>). LRRK2 possesses both kinase and GTPase activities. Most PD-linked LRRK2 mutations (e.g., G2019S) create an increase in kinase and GTPase activities, which play critical roles in PD pathogenesis (Liu et al., <xref ref-type="bibr" rid="B14">2011a</xref>). Unlike the G2019S mutation that is located in its kinase domain, G2385R is located in the WD40 domain. As the WD40 domain binds with several vesicle-associated proteins, the G2385R variant correlates with a reduced binding affinity of LRRK2 to synaptic vesicles (Piccoli et al., <xref ref-type="bibr" rid="B18">2014</xref>). G2385R-LRRK2 protein localize to the cytoplasm and form aggregates in transfected HEK293 cells (Tan et al., <xref ref-type="bibr" rid="B23">2007</xref>). Previous studies suggest that G2385R does not affect LRRK2 kinase activity (West et al., <xref ref-type="bibr" rid="B29">2007</xref>; Nichols et al., <xref ref-type="bibr" rid="B16">2010</xref>; Tan et al., <xref ref-type="bibr" rid="B22">2010</xref>), or may slightly reduce the kinase activity (Ho et al., <xref ref-type="bibr" rid="B7">2016</xref>; Carrion et al., <xref ref-type="bibr" rid="B3">2017</xref>). Therefore, G2385R may affect cellular functions via a different pathway than other PD-linked mutations in PD pathogenesis.</p>
<p>In this study, we are interested in understanding the roles of G2385R in affecting the neurodegeneration underlying PD pathogenesis using cell biology and pharmacology approaches. We found that overexpression of G2385R-LRRK2 induced neurotoxicity via an increase in oxidative stress, thereby activating the apoptotic pathway, and that curcumin (an antioxidant) significantly protected against G2385R-LRRK2-induced neurotoxicity. These findings provide novel insight into the mechanisms of G2385R-LRRK2-linked neurodegeneration and a potential treatment strategy for PD patients harboring G2385R.</p></sec>
<sec sec-type="materials and methods" id="s2">
<title>Materials and Methods</title>
<sec>
<title>Reagents</title>
<p>Antibodies against PARP (CST, 9532) and cleaved-PARP (CST, 9541) were from Cell Signaling, Inc. The anti-flag antibody, H<sub>2</sub>O<sub>2</sub>, and curcumin were from Sigma. Anti-LRRK2 [MJFF4 (c81-8)] was from MJFF. ECL goat anti-Rabbit IgG and ECL goat anti-Mouse IgG were from GE Healthcare (NA934V and NA931V, respectively). Mito-tracker and MitoSox were from Molecular Probe.</p></sec>
<sec>
<title>Plasmids, Cell Culture, and Transfection</title>
<p>WT-LRRK2, G2385R-LRRK2, and G2019S-LRRK2 constructs contain human LRRK2 cDNA with Flag-tags as described previously (Yang et al., <xref ref-type="bibr" rid="B31">2012</xref>; Thomas et al., <xref ref-type="bibr" rid="B24">2016</xref>). Human embryonic kidney (HEK293) cells were from the American Type Culture Collection (ATCC; Manassas, VA, USA) and were grown in Dulbecco&#x00027;s modified Eagle medium (DMEM; Gibco) with 10% heat-inactive fetal bovine serum (FBS; Gibco) and 1% penicillin&#x02013;streptomycin (Gibco) in a humidified 5% CO<sub>2</sub> atmosphere at 37&#x000B0;C. SH-SY5Y human neuroblastoma cells were from ATCC grown in Opti-Mem I media with 10% FBS and 1% penicillin-streptomycin. Cells were transfected with vectors, GFP, and various LRRK2 constructs using LipofectAMINE and a Plus reagent (Invitrogen, Carlsbad, CA) according to the manufacturer&#x00027;s protocol. For treatment experiments, curcumin (1 &#x003BC;M) was added 1 h prior to transfection and then transfected various constructs in transfection media without curcumin. Post-transfection lasted 4 h, and cells were incubated to normal medial with curcumin (1 &#x003BC;M in double-distilled H<sub>2</sub>O) for 48 h. H<sub>2</sub>O<sub>2</sub> (100 &#x003BC;M) was added 4 h post-transfection and until the end of the experiment.</p></sec>
<sec>
<title>Cell Viability Assays</title>
<p>SH-SY5Y cell viability assays were performed as described previously with slight modification (Smith et al., <xref ref-type="bibr" rid="B20">2005</xref>; Yang et al., <xref ref-type="bibr" rid="B31">2012</xref>; Thomas et al., <xref ref-type="bibr" rid="B24">2016</xref>). Briefly, post-transfection lasted 46 h, and neurons expressing GFP were imaged for 2 h with 20 min intervals on a Zeiss Axiovert 200 inverted microscope. The healthy GFP-positive cells were counted (where at least one process is smooth with two folds of cell body length) by an automatic program to detect healthy and smooth neurites and DAPI nuclei as described previously (Smith et al., <xref ref-type="bibr" rid="B20">2005</xref>; Yang et al., <xref ref-type="bibr" rid="B31">2012</xref>).</p></sec>
<sec>
<title>Mitochondrial Reactive Oxygen Species Assays</title>
<p>Cells were transfected with vector or various LRRK2 constructs for 12&#x02013;48 h. MitoSOX (5 &#x003BC;M) and MitoTracker (1 &#x003BC;M) were added 20 min before imaging as described previously (Wang et al., <xref ref-type="bibr" rid="B28">2020</xref>). The unused free MitoSox was washed away using PBS. Hoechst 33342 (blue) was used for nuclei staining. Fluorescent images were captured under a fluorescent microscopy image system (Carl Zeiss) with identical exposure settings. NIH image software was used to quantify the density of MitoSOX (Red), which represents the levels of mitochondrial superoxide. The MitoTracker was used to confirm the localization of MitoSOX in mitochondria.</p></sec>
<sec>
<title>Caspase-3/7 Activity Assay</title>
<p>The Nexcelom ViaStain&#x02122; Live Caspase-3/7 Detection kit (CSK-V0003-1, Nexcelom) was employed to detect caspase-3/7 activities according to manufactural protocol. The assay is based on the NucViewTM reagent with a nucleic-acid-binding dye linked to a fluorescent probe that is attached to a four-amino-acid peptide sequence DEVD (Asp-Glu-Val-Asp) to form a cell-membrane-permeable DEVD-DNA complex. During apoptosis, activated caspase-3/7 cleaves the DEVD-DNA dye complex to release the high-affinity DNA dye, which translocates to the nucleus and binds to the DNA, producing a bright green, fluorescent signal. When cells are healthy, the nucleic-acid dye is linked to the DEVD peptide sequence, and the dye is unable to bind to DNA, resulting in a lack of flourescence. Cells were transfected with a vector or LRRK2 constructs for 48 h and then incubated with NucViewTM reagent for 30 min. The green fluorescence was read using a Celigo fluorescent reader.</p></sec>
<sec>
<title>Primary Cortical Neurons Injury Assay</title>
<p>Mouse primary cortical neurons were generated from E16 embryos as described previously (Nucifora et al., <xref ref-type="bibr" rid="B17">2016</xref>), and they were cultured in Neurobasal medium with 2 mM Glutamax, 2% B27, and 1% PenStrep antibiotics. At 5 days <italic>in vitro</italic> (DIV), neurons were co-transfected with various LRRK2 plasmids and green fluorescent protein (GFP) at a ratio of 10:1 using Lipofectamine 2000 (Invitrogen) as described previously (16, 17). About 95% of GFP-positive cells expressed LRRK2 variants confirmed by co-immunostaining using anti-GFP and anti-LRRK2 antibodies. Curcumin was added 1 h prior to transfection, and H<sub>2</sub>O<sub>2</sub> (100 &#x003BC;M) was added 4 h post-transfection.</p>
<p>Neuronal injury assays were performed as described previously (Smith et al., <xref ref-type="bibr" rid="B20">2005</xref>; Liu et al., <xref ref-type="bibr" rid="B13">2016</xref>; Wang et al., <xref ref-type="bibr" rid="B27">2021</xref>). Neurons were imaged at end of experiments. Neurons with injury neurites were blindly quantified using NIH ImageJ software. Injured neurons were defined as displaying loss of neuronal projections, a disappearance of nerites, the presence of soma fragmentation, nerites with beading morphology, or a soma shape change from oval to completely circular. An arbitrary morphological score was assigned as either 100 for healthy cells or 0 for injured cells in each frame. The mean morphological score of all the cells was calculated. Data analysis was performed using a Gehan-Breslow test to determine the statistical difference between groups, followed by an All Pairwise Multiple Comparison (Holm-Sidak method) to identify the differences between groups.</p></sec>
<sec>
<title>Western Blot Analysis</title>
<p>Cells were collected using cell lysis buffer (Cell Signaling, Inc, CST-9803S) with 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na<sub>2</sub>EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 &#x003BC;g/ml leupeptin, and 1 mM PMSF. Cell lysates from each group were subjected to protein assays. An aliquot of 30 &#x003BC;g protein from each sample was resolved on 4&#x02013;12% NuPAGE Bis/Tris gels and transferred onto polyvinylidene difluoride membranes (Millipore). The membranes were blocked with 4% milk for 1 h, then incubated with various primary antibodies as indicated in Reagents section: anti-Flag (1:1,000 dilution), rabbit anti-PARP (1:1,000 dilution), and rabbit anti-cleaved PARP (1:1,000 dilution) followed by HRP-conjugated secondary antibodies: goat anti-Rabbit IgG (1:5,000 dilution) or goat anti-Mouse IgG (1:5,000 dilution). Protein bands were detected by ECL enhanced chemiluminescence reagents (PerkinElmer) as described previously (Li et al., <xref ref-type="bibr" rid="B11">2014</xref>; Yang et al., <xref ref-type="bibr" rid="B32">2018</xref>; Arbez et al., <xref ref-type="bibr" rid="B2">2020</xref>).</p></sec>
<sec>
<title>Statistical Analysis</title>
<p>Quantitative data represent the means &#x000B1; SEM of three separate experiments. There were three parallel reactions for each sample for all biochemistry experiments. Statistically significant differences among groups were analyzed by ANOVA by using the GraphPad Prism 5 software. The <italic>p</italic> value for significance was 0.05.</p></sec></sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>G2385R-LRRK2 Induced Toxicity in SH-SY5Y Cells</title>
<p>G2385R-LRRK2 was widely identified in the genetic studies of the Asian population (Zhang et al., <xref ref-type="bibr" rid="B34">2018</xref>). Its neurobiological function is understudied compared with the most common PD-linked mutation, G2019S-LRRK2. We found that transient expression of G2385R-LRRK2 significantly induced neurotoxicity in human neuroblastoma SH-SY5Y cells compared with vector cells alone or cells expressing wild-type (WT)-LRRK2 (<xref ref-type="fig" rid="F1">Figure 1</xref>). Compared to G2019S-LRRK2, G2385R-LRRK2 induced slightly less cell toxicity but exhibited no statistical difference. Thus, we only focused on G2385R-LRRK2 in this study.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>G2385R(GR)-LRRK2 induced neurodegeneration in SH-SY5Y cells. SH-SY5Y cells were co-transfected with GFP and vector or various LRRK2 constructs at 1:10 ration for 48 h. <bold>(A)</bold> Representative fluorescent images of cells in each group. <bold>(B)</bold> Cells viability. &#x0002A;<italic>p</italic> &#x0003C; 0.05, statistical significance between groups as indicated. NS, no significance; GS, G2019S.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnagi-13-754956-g0001.tif"/>
</fig></sec>
<sec>
<title>G2385R-LRRK2 Increased the ROS Level in Mitochondria and Activated Caspase 3/7</title>
<p>To study whether G2385R-LRRK2 alters mitochondrial ROS, MitoSOX florescent assays were used. The MitoSOX&#x02122; Red reagent can selectively label the production of mitochondrial superoxide under fluorescence microscopy. Expression of either WT or G2385R-LRRK2 increased the ROS level in mitochondria compared with vector cells (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>), while cells expressing G2385R-LRRK2 had more mitochondrial ROS than those of WT-LRRK2. Increased ROS (oxidative stress) could induce mitochondrial dysfunction and result in the activation of a caspase cascade. In fact, we found that expression of WT-LRRK2 slightly increased caspase 3/7 activities (<xref ref-type="fig" rid="F2">Figure 2C</xref>). However, G2385R-LRRK2 significantly increased caspase 3/7 activities compared with vector cells or cells expressing WT-LRRK2. Treatment with an antioxidant, curcumin, at 1 &#x003BC;M concentration (the most effective dose based on our pilot experiment) significantly protected against G2385R-induced neurodegeneration in SH-SY5Y cells compared with vehicle control (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>G2385R-LRRK2 significantly increased mitochondrial ROS and caspase-3/7 activation. SH-SY5Y cells were transfected with vector or various LRRK2 constructs as indicated for 12&#x02013;48 h. MitoTracker (green) and MitoSOX (red) reagents were added to cells 5 min before taking pictures. <bold>(A)</bold> Representative cell images at 12-h post transfection with MitoSOX. <bold>(B)</bold> Relative density of MitoSOX (red) fluorescence in each group at 12-h post transfection. <bold>(C)</bold> The lysate of cells expressing vector or various LRRK2 variants for 48 h were subjected to caspase-3/7 activity assays. <italic>p</italic> &#x0003C; 0.05 by ANOVA, &#x0002A; vs. cells expressing vector. <sup>&#x00023;</sup> vs. cells expressing WT-LRRK2.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnagi-13-754956-g0002.tif"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Curcumin protects against G2385R-LRRK2-induced neurotoxicity. Cells were transfected with vector or various LRRK2 constructs as indicated. Curcumin (1 &#x003BC;M) was added 1 h before transfection, and then 4-h post transfection till the end of the experiment. Cell viability was measured 48-h post-transfection. &#x0002A; <italic>p</italic> &#x0003C; 0.05, &#x0002A; vs. cells expressing vector. <sup>&#x00023;</sup> vs. cells expressing G2385R-LRRK2.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnagi-13-754956-g0003.tif"/>
</fig></sec>
<sec>
<title>H<sub>2</sub>O<sub>2</sub> Promotes G2385R-LRRK2-Induced Neurodegeneration in Primary Neurons</title>
<p>To further validate G2385R-LRRK2-induced neurodegeneration, we used mouse primary cortical neurons. Consistent with our findings in SH-SY5Y cells, expression of G2385R-LRRK2 dramatically induced neurite injury in mouse primary neurons compared with vector or WT-LRRK2 groups (<xref ref-type="fig" rid="F4">Figure 4</xref>). Curcumin significantly attenuated G2385R-induced neurite injury compared with the vehicle group (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>Curcumin protects against combined neurotoxicity of G2385R-LRRK2 and subtoxic H<sub>2</sub>O<sub>2</sub>. Mouse cortical primary neurons were co-transfected with GFP and vector or various LRRK2 constructs at 1:10 ratio, with or without a subtoxic dose of H<sub>2</sub>O<sub>2</sub> exposure and curcumin (1 &#x003BC;M). Neurons with injured neurites were measured. <bold>(A)</bold> Representative fluorescent images of neurons in each group. <bold>(B)</bold> Neurons with injury (white arrow) were counted in each group. &#x0002A; <italic>p</italic> &#x0003C; 0.05, statistical significance between groups as indicated.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnagi-13-754956-g0004.tif"/>
</fig>
<p>To further study the interaction between environmental stress and G2385R mutation, we added subtoxic doses of H<sub>2</sub>O<sub>2</sub> (100 &#x003BC;M) in neurons expressing vector or LRRK2 (WT or G2385R) variants. We found that H<sub>2</sub>O<sub>2</sub> promoted both WT-LRRK2 and G2385R-LRRK2-induced neurite injury (<xref ref-type="fig" rid="F4">Figure 4</xref>), but the neurons with G2385R were more vulnerable to H<sub>2</sub>O<sub>2</sub> than those of WT-LRRK2 cells. There was about a 3.5-fold increase in neurons with neurite injury in the G2385R-LRRK2 plus H<sub>2</sub>O<sub>2</sub> group compared to vector cells with H<sub>2</sub>O<sub>2</sub> (<xref ref-type="fig" rid="F4">Figure 4</xref>). Curcumin also protected against this combined neurotoxicity (H<sub>2</sub>O<sub>2</sub> and G2385R), up to 50% (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p></sec>
<sec>
<title>Curcumin Attenuated H<sub>2</sub>O<sub>2</sub> and G2385R-LRRK2-Induced Mitochondrial ROS and Caspase-3/7 Activation</title>
<p>Exposure of subtoxic doses of H<sub>2</sub>O<sub>2</sub> (100 &#x003BC;M) in SH-SY5Y cells also dramatically increased both WT-LRRK2- and G2385R-LRRK2-induced mitochondrial ROS levels compared to no exposure control group (<xref ref-type="fig" rid="F5">Figure 5A</xref>), while the ROS increased more in cells expressing the G2385R variant. Moreover, Curcumin treatment significantly attenuated the mitochondrial ROS induced by H<sub>2</sub>O<sub>2</sub> and G2385R-LRRK2 compared with vehicle control (<xref ref-type="fig" rid="F5">Figure 5A</xref>). Exposure of subtoxic doses of H<sub>2</sub>O<sub>2</sub> also dramatically increased both WT-LRRK2 and G2385R-LRRK2-induced caspase-3/7 activation compared to those cells without H<sub>2</sub>O<sub>2</sub> (<xref ref-type="fig" rid="F5">Figure 5B</xref>). Curcumin treatment significantly reduced caspase-3/7 activation (<xref ref-type="fig" rid="F5">Figure 5B</xref>).</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>Curcumin reduced H<sub>2</sub>O<sub>2</sub> and G2385R-LRRK2-induced mitochondrial ROS and caspase-3/7 activation. SH-SY5Y cells were co-transfected with vector or various LRRK2 constructs with or without a subtoxic dose of H<sub>2</sub>O<sub>2</sub> exposure and curcumin (1 &#x003BC;M) for 12&#x02013;48 h. <bold>(A)</bold> Mitochondrial ROS in each group was measured at 12 h after treatment of H<sub>2</sub>O<sub>2</sub> and curcumin. <bold>(B)</bold> Caspase-3/7 activities were measured at 48 h after treatment of H<sub>2</sub>O<sub>2</sub> and curcumin. &#x0002A; <italic>p</italic> &#x0003C; 0.05, statistical significance between groups as indicated.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnagi-13-754956-g0005.tif"/>
</fig></sec>
<sec>
<title>Curcumin Attenuated PARP Cleavage Induced by H<sub>2</sub>O<sub>2</sub> and G2385R-LRRK2</title>
<p>PARP is an enzyme in the nucleus and can be cleaved (inactive) by active caspase-3 during apoptosis. To assess whether G2385R alters PARP cleavage, we used HEK293 cells transiently transfected with LRRK2 constructs as these cells have high transfected efficiency (over 80%) and extract the protein, then perform western blot analysis. We found that expression of mutant G2385R-LRRK2 significantly increased PARP cleavage compared to vector cells (<xref ref-type="fig" rid="F6">Figure 6</xref>). Moreover, H<sub>2</sub>O<sub>2</sub> dramatically increased G2385R-LRRK2-induced PARP cleavage compared to those cells without H<sub>2</sub>O<sub>2</sub> (<xref ref-type="fig" rid="F6">Figure 6</xref>). While curcumin treatment significantly attenuated PARP cleavage-induced by H<sub>2</sub>O<sub>2</sub> and G2385R-LRRK2 compared with vehicle controls (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption><p>Curcumin reduced H<sub>2</sub>O<sub>2</sub> and G2385R-LRRK2-induced PARP cleavage. HEK293 cells were co-transfected with vector or various LRRK2 constructs with or without a subtoxic dose of H<sub>2</sub>O<sub>2</sub> exposure and curcumin (1 &#x003BC;M) for 48 h. Cell lysates were subjected to western blot analysis using antibodies against PARP, cleavage PARP, and actin. <bold>(A)</bold> Representative blot from three separated experiments. <bold>(B)</bold> Quantification of <bold>(A)</bold> &#x0002A; <italic>p</italic> &#x0003C; 0.05, statistical significance between groups as indicated.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnagi-13-754956-g0006.tif"/>
</fig></sec></sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In this study, we demonstrated that expression of G2385R-LRRK2 induced neurodegeneration in human neuroblastoma SH-SY5Y and mouse primary neurons. G2385R-LRRK2 increased mitochondrial ROS, activated caspase-3/7, and increased PARP cleavage, resulting in neurotoxicity. Treatment with curcumin (an antioxidant) significantly protected against G2385R-LRRK2-induced neurodegeneration by reducing mitochondrial ROS, caspase activation, and PARP cleavage. We also found that the cellular environmental stressor, H<sub>2</sub>O<sub>2</sub>, significantly promotes G2385R-induced neurotoxicity by increasing mitochondrial ROS, caspase-3/7 activation, and PARP cleavage, while curcumin attenuated this combined neurotoxicity.</p>
<p>G2385R-LRRK2 variant is associated with an increased risk of PD in the Chinese population, and subjects harboring this variant were &#x0007E;2.5 times more likely to develop PD (Healy et al., <xref ref-type="bibr" rid="B6">2008</xref>; Zhang et al., <xref ref-type="bibr" rid="B34">2018</xref>). G2385R is in the WD40 domain, which is involved in a variety of cellar functions such as signal transduction, pre-mRNA processing, and cytoskeleton assembly. The G residue is hydrophobic, while R has a positive charge and is hydrophilic. G2385R alters the motifs from 2,385 to 2,390 (GLidCV), a potential N-myristoylation site of LRRK2 protein, which has implications in posttranslational N-myristoylation related to apoptotic events (Zha et al., <xref ref-type="bibr" rid="B33">2000</xref>; Vilas et al., <xref ref-type="bibr" rid="B25">2006</xref>). As is consistent with the structural and genetic analysis, we found that expression of G2385R-LRRK2 significantly reduced cell viability in SH-SY5Y cells and increase neurite injury in the primary neurons due to an increase in mitochondrial ROS, activation of caspase 3/7, and cleavage of PARP, which are key events in apoptosis.</p>
<p>Oxidative stress plays a critical role in aging and neurodegenerative diseases including PD. Oxidative stress has been reported in various cellular and animal PD models and post-mortem human PD specimens (Abou-Sleiman et al., <xref ref-type="bibr" rid="B1">2006</xref>). We and others previously found that PD risk mutant alleles (e.g., A53T alpha-synuclein, G2019S-LRRK2) causes more severe neurotoxicity in the presence of oxidative stress environment (Smith et al., <xref ref-type="bibr" rid="B20">2005</xref>; West et al., <xref ref-type="bibr" rid="B29">2007</xref>; Li et al., <xref ref-type="bibr" rid="B12">2010</xref>; Liu et al., <xref ref-type="bibr" rid="B15">2011b</xref>). The generation of ROS within neuronal cells can trigger stress-linked signaling pathway, resulting in the activation of a caspase cascade and apoptosis. In this study, we found that subtoxic H<sub>2</sub>O<sub>2</sub> did not alter vector control cells but significantly potentiated both WT-LRRK2 and G2385R-LRRK2-induced neurotoxicity by an increase in mitochondrial ROS, caspase-3/7 activation, and PARP cleavage. Cells with G2385R-LRRK2 are more vulnerable than cells with WT-LRRK2. This is consistent with previous studies that oxidative stress promotes G2385R-LRRK2-induced cell death and protein aggregation in HEK293 cells (Tan et al., <xref ref-type="bibr" rid="B23">2007</xref>). Together, these findings indicate that G2385R alters LRRK2 function and triggers ROS generation and caspase/PARP-linked apoptotic pathways.</p>
<p>Curcumin is a potent antioxidant (Zhao et al., <xref ref-type="bibr" rid="B35">1989</xref>; Gupta et al., <xref ref-type="bibr" rid="B5">2011</xref>; Liu et al., <xref ref-type="bibr" rid="B15">2011b</xref>). The free radical scavenging effect of curcumin is several times higher than that of vitamin E (Zhao et al., <xref ref-type="bibr" rid="B35">1989</xref>). Previous studies have shown that curcumin can be protected against neurodegeneration in various PD models, including reduction of the damage of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), G2019S-LRRK2 on dopaminergic neurons (Rajeswari, <xref ref-type="bibr" rid="B19">2006</xref>; Wang et al., <xref ref-type="bibr" rid="B26">2009</xref>). Our results showed that curcumin dramatically attenuated G2385R-induced neurodegeneration and further protected against the combined neurotoxicity induced by both H<sub>2</sub>O<sub>2</sub> and G2385R. The protective effect of curcumin is through reduction the mitochondrial ROS, caspase-3/7 activation, and PARP cleavage. Curcumin is a food additive with a large safety window. There are no adverse or toxic effects with doses from 2,000 to 8,000 mg/day according to clinical studies (Srimal and Dhawan, <xref ref-type="bibr" rid="B21">1973</xref>; Hsu and Cheng, <xref ref-type="bibr" rid="B8">2007</xref>). Curcumin protects against neuronal degeneration in other <italic>in vitro</italic> and <italic>in vivo</italic> models of neurodegenerative diseases (e.g., Alzheimer&#x00027;s disease) as well. Thus, curcumin could be a potential prevention or treatment agent for G2385R-LRRK2-linked PD or related disorders.</p>
<p>In conclusion, our findings demonstrated that G2385R-LRRK2 induced neurodegeneration and H<sub>2</sub>O<sub>2</sub> significantly potentiated G2385R neurotoxicity in cultured SH-SY5Y cells and primary neurons. Curcumin protected against combined neurotoxicity of G2385R-LRRK2 and H<sub>2</sub>O<sub>2</sub> via reducing mitochondrial ROS, caspase-3/7 activation, and PARP cleavage. These findings not only provide a novel understanding of G2385R roles in neurodegeneration and environment interaction but also provide a pharmacological approach for intervention for G2385R-LRRK2-linked PD.</p></sec>
<sec sec-type="data-availability" id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.</p></sec>
<sec id="s6">
<title>Author Contributions</title>
<p>JZ, CL, and WS: conception and design of the study. JZ, KL, XW, AS, BN, ZL, CL, CR, and WS: acquisition, analysis, and interpretation of data. JZ and WS: drafting the manuscript and statistical analysis. All authors contributed to the article and approved the submitted version.</p></sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>This work is supported by NIH Grants: R01NS093383, R01NS119208, and R01NS120879 to WS.</p></sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abou-Sleiman</surname> <given-names>P. M.</given-names></name> <name><surname>Muqit</surname> <given-names>M. M.</given-names></name> <name><surname>Wood</surname> <given-names>N. W.</given-names></name></person-group> (<year>2006</year>). <article-title>Expanding insights of mitochondrial dysfunction in Parkinson&#x00027;s disease</article-title>. <source>Nat. Rev. Neurosci.</source> <volume>7</volume>, <fpage>207</fpage>&#x02013;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1038/nrn1868</pub-id><pub-id pub-id-type="pmid">16495942</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arbez</surname> <given-names>N.</given-names></name> <name><surname>He</surname> <given-names>X. F.</given-names></name> <name><surname>Huang</surname> <given-names>Y.</given-names></name> <name><surname>Ren</surname> <given-names>M.</given-names></name> <name><surname>Liang</surname> <given-names>Y.</given-names></name> <name><surname>Nucifora</surname> <given-names>F. C.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice</article-title>. <source>Hum. Mol. Genet</source>. <volume>29</volume>, <fpage>580</fpage>&#x02013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddz271</pub-id><pub-id pub-id-type="pmid">31813996</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carrion</surname> <given-names>M. D. P.</given-names></name> <name><surname>Marsicano</surname> <given-names>S.</given-names></name> <name><surname>Daniele</surname> <given-names>F.</given-names></name> <name><surname>Marte</surname> <given-names>A.</given-names></name> <name><surname>Pischedda</surname> <given-names>F.</given-names></name> <name><surname>Di</surname> <given-names>C. E.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions</article-title>. <source>Sci. Rep.</source> <volume>7</volume>:<fpage>5377</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-05760-9</pub-id><pub-id pub-id-type="pmid">28710481</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>L. N.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Karlins</surname> <given-names>E.</given-names></name> <name><surname>Saito</surname> <given-names>L.</given-names></name> <name><surname>Mejia-Santana</surname> <given-names>H.</given-names></name> <name><surname>Harris</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Frequency of LRRK2 mutations in early- and late-onset Parkinson disease</article-title>. <source>Neurology</source> <volume>67</volume>, <fpage>1786</fpage>&#x02013;<lpage>1791</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000244345.49809.36</pub-id><pub-id pub-id-type="pmid">17050822</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>S. C.</given-names></name> <name><surname>Prasad</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>J. H.</given-names></name> <name><surname>Patchva</surname> <given-names>S.</given-names></name> <name><surname>Webb</surname> <given-names>L. J.</given-names></name> <name><surname>Priyadarsini</surname> <given-names>I. K.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Multitargeting by curcumin as revealed by molecular interaction studies</article-title>. <source>Nat. Prod. Rep.</source> <volume>28</volume>, <fpage>1937</fpage>&#x02013;<lpage>1955</lpage>. <pub-id pub-id-type="doi">10.1039/c1np00051a</pub-id><pub-id pub-id-type="pmid">21979811</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname> <given-names>D. G.</given-names></name> <name><surname>Falchi</surname> <given-names>M.</given-names></name> <name><surname>O&#x00027;Sullivan</surname> <given-names>S. S.</given-names></name> <name><surname>Bonifati</surname> <given-names>V.</given-names></name> <name><surname>Durr</surname> <given-names>A.</given-names></name> <name><surname>Bressman</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&#x00027;s disease: a case-control study</article-title>. <source>Lancet Neurol.</source> <volume>7</volume>, <fpage>583</fpage>&#x02013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(08)70117-0</pub-id><pub-id pub-id-type="pmid">18539534</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>D. H.</given-names></name> <name><surname>Jang</surname> <given-names>J.</given-names></name> <name><surname>Joe</surname> <given-names>E. H.</given-names></name> <name><surname>Son</surname> <given-names>I.</given-names></name> <name><surname>Seo</surname> <given-names>H.</given-names></name> <name><surname>Seol</surname> <given-names>W.</given-names></name></person-group> (<year>2016</year>). <article-title>G2385R and I2020T mutations increase LRRK2 GTPase activity</article-title>. <source>Biomed Res. Int.</source> <volume>2016</volume>:<fpage>7917128</fpage>. <pub-id pub-id-type="doi">10.1155/2016/7917128</pub-id><pub-id pub-id-type="pmid">27314038</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>C. H.</given-names></name> <name><surname>Cheng</surname> <given-names>A. L.</given-names></name></person-group> (<year>2007</year>). <article-title>Clinical studies with curcumin</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>595</volume>, <fpage>471</fpage>&#x02013;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-46401-5_21</pub-id><pub-id pub-id-type="pmid">17569225</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalia</surname> <given-names>L. V.</given-names></name> <name><surname>Lang</surname> <given-names>A. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Parkinson&#x00027;s disease</article-title>. <source>Lancet</source> <volume>386</volume>, <fpage>896</fpage>&#x02013;<lpage>912</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61393-3</pub-id><pub-id pub-id-type="pmid">25904081</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>A. J.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Alcalay</surname> <given-names>R. N.</given-names></name> <name><surname>Mejia-Santana</surname> <given-names>H.</given-names></name> <name><surname>Saunders-Pullman</surname> <given-names>R.</given-names></name> <name><surname>Bressman</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry</article-title>. <source>Mov. Disord.</source> <volume>32</volume>, <fpage>1432</fpage>&#x02013;<lpage>1438</lpage>. <pub-id pub-id-type="doi">10.1002/mds.27059</pub-id><pub-id pub-id-type="pmid">28639421</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>T.</given-names></name> <name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Smith</surname> <given-names>W. W.</given-names></name></person-group> (<year>2014</year>). <article-title>Synphilin-1 binds ATP and regulates intracellular energy status</article-title>. <source>PLoS ONE</source> <volume>9</volume>:<fpage>e115233</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0115233</pub-id><pub-id pub-id-type="pmid">25545246</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Moore</surname> <given-names>D. J.</given-names></name> <name><surname>Xiong</surname> <given-names>Y.</given-names></name> <name><surname>Dawson</surname> <given-names>T. M.</given-names></name> <name><surname>Dawson</surname> <given-names>V. L.</given-names></name></person-group> (<year>2010</year>). <article-title>Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2</article-title>. <source>J. Biol. Chem.</source> <volume>285</volume>, <fpage>29569</fpage>&#x02013;<lpage>29576</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.127639</pub-id><pub-id pub-id-type="pmid">20595391</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Li</surname> <given-names>T.</given-names></name> <name><surname>Thomas</surname> <given-names>J. M.</given-names></name> <name><surname>Pei</surname> <given-names>Z.</given-names></name> <name><surname>Jiang</surname> <given-names>H.</given-names></name> <name><surname>Engelender</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson&#x00027;s disease models</article-title>. <source>Hum. Mol. Genet.</source> <volume>25</volume>, <fpage>672</fpage>&#x02013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddv504</pub-id><pub-id pub-id-type="pmid">26744328</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Hamamichi</surname> <given-names>S.</given-names></name> <name><surname>Lee</surname> <given-names>B. D.</given-names></name> <name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Ray</surname> <given-names>A.</given-names></name> <name><surname>Caldwell</surname> <given-names>G. A.</given-names></name> <etal/></person-group>. (<year>2011a</year>). <article-title>Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in <italic>Caenorhabditis elegans</italic> and Drosophila Parkinson&#x00027;s disease models</article-title>. <source>Hum. Mol. Genet.</source> <volume>20</volume>, <fpage>3933</fpage>&#x02013;<lpage>3942</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddr312</pub-id><pub-id pub-id-type="pmid">21768216</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Yu</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Ross</surname> <given-names>C. A.</given-names></name> <name><surname>Smith</surname> <given-names>W. W.</given-names></name></person-group> (<year>2011b</year>). <article-title>Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism</article-title>. <source>Pharmacol. Res</source>. <volume>63</volume>, <fpage>439</fpage>&#x02013;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2011.01.004</pub-id>.<pub-id pub-id-type="pmid">21237271</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname> <given-names>R. J.</given-names></name> <name><surname>Dzamko</surname> <given-names>N.</given-names></name> <name><surname>Morrice</surname> <given-names>N. A.</given-names></name> <name><surname>Campbell</surname> <given-names>D. G.</given-names></name> <name><surname>Deak</surname> <given-names>M.</given-names></name> <name><surname>Ordureau</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>14-3-3 binding to LRRK2 is disrupted by multiple Parkinson&#x00027;s disease-associated mutations and regulates cytoplasmic localization</article-title>. <source>Biochem. J.</source> <volume>430</volume>, <fpage>393</fpage>&#x02013;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20100483</pub-id><pub-id pub-id-type="pmid">20642453</pub-id></citation></ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nucifora</surname> <given-names>F. C.</given-names></name> <name><surname>Nucifora</surname> <given-names>L. G.</given-names></name> <name><surname>Ng</surname> <given-names>C. H.</given-names></name> <name><surname>Arbez</surname> <given-names>N.</given-names></name> <name><surname>Guo</surname> <given-names>Y.</given-names></name> <name><surname>Roby</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1</article-title>. <source>Nat. Commun.</source> <volume>7</volume>, <fpage>11792</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11792</pub-id><pub-id pub-id-type="pmid">27273569</pub-id></citation></ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piccoli</surname> <given-names>G.</given-names></name> <name><surname>Onofri</surname> <given-names>F.</given-names></name> <name><surname>Cirnaru</surname> <given-names>M. D.</given-names></name> <name><surname>Kaiser</surname> <given-names>C. J.</given-names></name> <name><surname>Jagtap</surname> <given-names>P.</given-names></name> <name><surname>Kastenm&#x000FC;ller</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain</article-title>. <source>Mol. Cell. Biol.</source> <volume>34</volume>, <fpage>2147</fpage>&#x02013;<lpage>2161</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00914-13</pub-id><pub-id pub-id-type="pmid">24687852</pub-id></citation></ref>
<ref id="B19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajeswari</surname> <given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>10</volume>, <fpage>157</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">16910344</pub-id></citation></ref>
<ref id="B20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>W. W.</given-names></name> <name><surname>Pei</surname> <given-names>Z.</given-names></name> <name><surname>Jiang</surname> <given-names>H.</given-names></name> <name><surname>Moore</surname> <given-names>D. J.</given-names></name> <name><surname>Liang</surname> <given-names>Y.</given-names></name> <name><surname>West</surname> <given-names>A. B.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration</article-title>. <source>Proc. Natl. Acad. Sci. USA.</source> <volume>102</volume>, <fpage>18676</fpage>&#x02013;<lpage>18681</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0508052102</pub-id><pub-id pub-id-type="pmid">16352719</pub-id></citation></ref>
<ref id="B21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srimal</surname> <given-names>R. C.</given-names></name> <name><surname>Dhawan</surname> <given-names>B. N.</given-names></name></person-group> (<year>1973</year>). <article-title>Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent</article-title>. <source>J. Pharm. Pharmacol.</source> <volume>25</volume>, <fpage>447</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1111/j.2042-7158.1973.tb09131.x</pub-id><pub-id pub-id-type="pmid">4146582</pub-id></citation></ref>
<ref id="B22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>E. K.</given-names></name> <name><surname>Peng</surname> <given-names>R.</given-names></name> <name><surname>Teo</surname> <given-names>Y. Y.</given-names></name> <name><surname>Tan</surname> <given-names>L. C.</given-names></name> <name><surname>Angeles</surname> <given-names>D.</given-names></name> <name><surname>Ho</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study</article-title>. <source>Hum. Mutat.</source> <volume>31</volume>, <fpage>561</fpage>&#x02013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21225</pub-id><pub-id pub-id-type="pmid">20186690</pub-id></citation></ref>
<ref id="B23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>E. K.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Skipper</surname> <given-names>L.</given-names></name> <name><surname>Tan</surname> <given-names>M. G.</given-names></name> <name><surname>Di</surname> <given-names>F. A.</given-names></name> <name><surname>Sun</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>The LRRK2 Gly2385Arg variant is associated with Parkinson&#x00027;s disease: genetic and functional evidence</article-title>. <source>Hum. Genet.</source> <volume>120</volume>, <fpage>857</fpage>&#x02013;<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-006-0268-0</pub-id><pub-id pub-id-type="pmid">17019612</pub-id></citation></ref>
<ref id="B24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>J. M.</given-names></name> <name><surname>Li</surname> <given-names>T.</given-names></name> <name><surname>Yang</surname> <given-names>W.</given-names></name> <name><surname>Xue</surname> <given-names>F.</given-names></name> <name><surname>Fishman</surname> <given-names>P. S.</given-names></name> <name><surname>Smith</surname> <given-names>W. W.</given-names></name></person-group> (<year>2016</year>). <article-title>68 and FX2149 attenuate mutant LRRK2-R1441C-induced neural transport impairment</article-title>. <source>Front. Aging Neurosci.</source> <volume>8</volume>:<fpage>337</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2016.00337</pub-id><pub-id pub-id-type="pmid">28119604</pub-id></citation></ref>
<ref id="B25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilas</surname> <given-names>G. L.</given-names></name> <name><surname>Corvi</surname> <given-names>M. M.</given-names></name> <name><surname>Plummer</surname> <given-names>G. J.</given-names></name> <name><surname>Seime</surname> <given-names>A. M.</given-names></name> <name><surname>Lambkin</surname> <given-names>G. R.</given-names></name> <name><surname>Berthiaume</surname> <given-names>L. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Posttranslational myristoylation of caspase-activated p21-activated protein kinase 2 (PAK2) potentiates late apoptotic events</article-title>. <source>Proc. Natl. Acad. Sci. USA.</source> <volume>103</volume>, <fpage>6542</fpage>&#x02013;<lpage>6547</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0600824103</pub-id><pub-id pub-id-type="pmid">16617111</pub-id></citation></ref>
<ref id="B26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Du</surname> <given-names>XX</given-names></name> <name><surname>Jiang</surname> <given-names>H.</given-names></name> <name><surname>Xie</surname> <given-names>J. X.</given-names></name></person-group> (<year>2009</year>). <article-title>Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells</article-title>. <source>Biochem. Pharmacol.</source> <volume>78</volume>, <fpage>178</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2009.03.031</pub-id><pub-id pub-id-type="pmid">19464433</pub-id></citation></ref>
<ref id="B27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Guo</surname> <given-names>G.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Aebez</surname> <given-names>N.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Liu</surname> <given-names>C. F.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Mutant-TMEM230-induced neurodegeneration and impaired axonal mitochondrial transport</article-title>. <source>Hum. Mol. Genet.</source> <volume>30</volume>, <fpage>1535</fpage>&#x02013;<lpage>1542</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddab128</pub-id><pub-id pub-id-type="pmid">34002226</pub-id></citation></ref>
<ref id="B28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Wu</surname> <given-names>T.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Guo</surname> <given-names>G.</given-names></name> <name><surname>He</surname> <given-names>X.</given-names></name> <name><surname>Pei</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Transmembrane protein 230 mediates a poly(ADP-ribose) polymerase-1-linked apoptosis</article-title>. <source>Front. Aging Neurosci.</source> <volume>12</volume>:<fpage>235</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2020.00235</pub-id><pub-id pub-id-type="pmid">32848711</pub-id></citation></ref>
<ref id="B29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>West</surname> <given-names>A. B.</given-names></name> <name><surname>Moore</surname> <given-names>D. J.</given-names></name> <name><surname>Choi</surname> <given-names>C.</given-names></name> <name><surname>Andrabi</surname> <given-names>S. A.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Dikeman</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Parkinson&#x00027;s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity</article-title>. <source>Hum. Mol. Genet.</source> <volume>16</volume>, <fpage>223</fpage>&#x02013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddl471</pub-id><pub-id pub-id-type="pmid">17200152</pub-id></citation></ref>
<ref id="B30">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>C. L.</given-names></name> <name><surname>Pan</surname> <given-names>J. L.</given-names></name> <name><surname>Wang</surname> <given-names>W. W.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>S. F.</given-names></name> <name><surname>Gan</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>The association between the LRRK2 G2385R variant and the risk of Parkinson&#x00027;s disease: a meta-analysis based on 23 case-control studies</article-title>. <source>Neurol. Sci.</source> <volume>35</volume>, <fpage>1495</fpage>&#x02013;<lpage>1504</lpage>. <pub-id pub-id-type="doi">10.1007/s10072-014-1878-2</pub-id><pub-id pub-id-type="pmid">25027012</pub-id></citation></ref>
<ref id="B31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Li</surname> <given-names>T.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Arbez</surname> <given-names>N.</given-names></name> <name><surname>Yan</surname> <given-names>J.</given-names></name> <name><surname>Moran</surname> <given-names>T. H.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin</article-title>. <source>Neurobiol. Dis.</source> <volume>47</volume>, <fpage>385</fpage>&#x02013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2012.05.020</pub-id><pub-id pub-id-type="pmid">22668778</pub-id></citation></ref>
<ref id="B32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Thomas</surname> <given-names>J. M.</given-names></name> <name><surname>Li</surname> <given-names>T.</given-names></name> <name><surname>Lee</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Smith</surname> <given-names>W. W.</given-names></name></person-group> (<year>2018</year>). <article-title>The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration</article-title>. <source>Biochem. Cell Biol</source>. <volume>96</volume>, <fpage>441</fpage>&#x02013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1139/bcb-2017-0262</pub-id><pub-id pub-id-type="pmid">29268033</pub-id></citation></ref>
<ref id="B33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zha</surname> <given-names>J.</given-names></name> <name><surname>Weiler</surname> <given-names>S.</given-names></name> <name><surname>Oh</surname> <given-names>K. J.</given-names></name> <name><surname>Wei</surname> <given-names>M. C.</given-names></name> <name><surname>Korsmeyer</surname> <given-names>S. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis</article-title>. <source>Science</source> <volume>290</volume>, <fpage>1761</fpage>&#x02013;<lpage>1765</lpage>. <pub-id pub-id-type="doi">10.1126/science.290.5497.1761</pub-id><pub-id pub-id-type="pmid">11099414</pub-id></citation></ref>
<ref id="B34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J. R.</given-names></name> <name><surname>Jin</surname> <given-names>H.</given-names></name> <name><surname>Li</surname> <given-names>K.</given-names></name> <name><surname>Mao</surname> <given-names>C. J.</given-names></name> <name><surname>Yang</surname> <given-names>Y. P.</given-names></name> <name><surname>Wang</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Genetic analysis of LRRK2 in Parkinson&#x00027;s disease in Han Chinese population</article-title>. <source>Neurobiol. Aging</source> <volume>72</volume>, <fpage>187.e5</fpage>&#x02013;<lpage>187.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.06.036</pub-id><pub-id pub-id-type="pmid">30049590</pub-id></citation></ref>
<ref id="B35">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>B. L.</given-names></name> <name><surname>Li</surname> <given-names>X. J.</given-names></name> <name><surname>He</surname> <given-names>R. G.</given-names></name> <name><surname>Cheng</surname> <given-names>S. J.</given-names></name> <name><surname>Xin</surname> <given-names>W. J.</given-names></name></person-group> (<year>1989</year>). <article-title>Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals</article-title>. <source>Cell Biophys.</source> <volume>14</volume>, <fpage>175</fpage>&#x02013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1007/BF02797132</pub-id><pub-id pub-id-type="pmid">2472207</pub-id></citation></ref>
</ref-list> 
</back>
</article>